Herein, we review current treatment indications and therapeutic options, followed by evidence-based recommendations for the choice of therapy in primary and relapsed CLL. Supported by phase III trial data, combined chemotherapy with fludarabine and cyclophosphamide is considered the standard first-line ...
EP: 1.Current Front-Line Treatment Options for CLL in 2023 EP: 2.Exploring BTKi Monotherapy in CLL: Long-Term Updates from ELEVATE-TN and SEQUOIA EP: 3.Strategies for Managing Treatment-Naïve CLL with High-Risk Features EP: 4.Impact of Off-Target AEs and Treatment Resistance on Evolving...
A combination of ibrutinib and rituximab keeps patients with a common form of leukemia alive and disease-free longer than the current treatment regimen, according to a phase 3 trial results published today. Patients with chronic lymphocytic leukemia (CLL) will likely see a new s...
Recent developments in the treatment of patients with chronic lymphocytic leukemia (CLL) have created new, unanswered questions and left clinicians scrambling to keep up with the pace of change, said Danielle Brander, MD. However, she said that is a good problem to have. “For patients who I ...
Danielle Brander, MD, assistant professor at Duke University and the Duke Cancer Institute, discusses the current treatment landscape in the frontline setting for patients with chronic lymphocytic leukemia (CLL). There have been changes for this patient population in the frontline, as well as those ...
However, patients with progressive and more advanced CLL require treatment. For many years, chlorambucil with or without corticosteroids was used in previously untreated patients with CLL. More recently, purine nucleoside analogues (PNAs) [fludarabine, cladribine and pentostatin] have been included in ...
EP: 1.Factors for Consideration When Choosing a Treatment for Patients With CLL Now Viewing EP: 2.The Current Treatment Landscape in CLL With the Advent of Novel Therapy Agents EP: 3.BTK Inhibitor Investigations in the Frontline Treatment of CLL: Updates from ASH 2023 ...
Navigating Treatment Decision-Making Challenges in CLL Management Acalabrutinib Regimen Demonstrates Combinatorial Benefit in MCL Acalabrutinib Plus Chemotherapy Provides Cover for High-Risk Patients in MCL Hematologic Oncology | Leukemia | Oncology Journal ...
Indication for therapy HCL usually has an indolent disease course, and similarly to chronic lymphocytic leukemia (CLL), patients who are asymptomatic do not require therapy. However, treatment should be considered for symptomatic or cytopenic patients. Treatment is indicated for patients with significant...
Historically, treatment of chronic lymphocytic leukemia (CLL) essentially had been palliative. During the past two decades, effective new therapies for the treatment of CLL have emerged. The advent of fludarabine, a purine analog with activity against chlorambucil-resistant CLL, showed promising results...